CD58 and neoplasm: High expression and interaction activity of CD2 and CD58 between CTLs and tumor cells in BCBM were identified, supporting downstream experimental validation and providing molecular evidence for the regulatory role of the CD2–CD58 axis in immune responses and tumor progression.